Parirenyatwa General Hospital a hospital in Harare and is the largest medical centre in Zimbabwe. The hospital was formerly known as the Andrew Fleming Hospital and was named after the principal medical officer to the British South Africa Company.

There are 5,000 beds in Parirenyatwa Hospital.

During the past decade, Parirenyatwa Hospital conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Parirenyatwa Hospital" #1 sponsor was "University of Zimbabwe" with 3 trials, followed by "AIDS Malignancy Consortium" with 1 trials sponsored, "Population Health Research Institute" with 1 trials sponsored, "Queen Mary University of London" with 1 trials sponsored and "University College, London" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Parirenyatwa Hospital" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Biomedical Research and Training Institute, Zimbabwe" with 1 trials as a collaborator, "Centers for Disease Control and Prevention" with 1 trials as a collaborator, "IBDnet" with 1 trials as a collaborator and "Ministry of Health and Child Welfare, Zimbabwe" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Parirenyatwa Hospital" are "Cervical Adenocarcinoma" (1 trials), "Cervical Adenosquamous Carcinoma" (1 trials), "Cervical Squamous Cell Carcinoma, Not Otherwise Specified" (1 trials), "Crohn Disease" (1 trials) and "Cryptococcal Meningitis" (1 trials). Many other conditions were trialed in "Parirenyatwa Hospital" in a lesser frequency.

Most popular intervention types in "Parirenyatwa Hospital" are "Drug" (3 trials), "Other" (2 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Budesonide" (1 trials), "Carboplatin" (1 trials), "Cisplatin" (1 trials), "Colostrum high protein powder (Neovite)" (1 trials) and "N-Acetyl Glucosamine (GInNAC)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Parirenyatwa Hospital" are 6 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Parirenyatwa Hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Parirenyatwa Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Parirenyatwa Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".